09:26 AM EST, 02/27/2025 (MT Newswires) -- Viridian Therapeutics ( VRDN ) reported Thursday a Q4 net loss of $0.81 per diluted share, narrowing from a loss of $0.97 per share a year earlier.

Analysts polled by FactSet expected a loss of $1.04 per share.

Revenue for the quarter ended Dec. 31 was $72,000, flat compared with $72,000 a year earlier.

Analysts surveyed by FactSet expected zero revenue.

As of Dec. 31, the company said it had $717.6 million in cash and or cash equivalents on hand, and short-term investments, which is expected to fund operations through H2 of 2027.

VRDN shares were 0.4% lower ahead of Thursday's opening bell.